ESR1 and endometrial cancer: ER-mediated transcriptional activity was measured in the Ishikawa endometrial cancer cell line using the method previously described [46], demonstrating that NO-DMA acts an antiestrogen with potency (IC50 = 3.9±1.3 nM) similar to that of DMA (0.1±0.1 nM) and FDMA (1.4±0.4 nM).